175 related articles for article (PubMed ID: 34864527)
21. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.
Revollo B; Viñuela L; de la Mora L; García F; Noguera-Julián M; Parera M; Paredes R; Llibre JM
J Antimicrob Chemother; 2022 May; 77(6):1738-1740. PubMed ID: 35274144
[TBL] [Abstract][Full Text] [Related]
22. Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
Fulcher JA; Du Y; Zhang TH; Sun R; Landovitz RJ
Clin Infect Dis; 2018 Aug; 67(5):791-794. PubMed ID: 29933437
[TBL] [Abstract][Full Text] [Related]
23. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
24. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572).
Vavro C; Hasan S; Madsen H; Horton J; DeAnda F; Martin-Carpenter L; Sato A; Cuffe R; Chen S; Underwood M; Nichols G
Antimicrob Agents Chemother; 2013 Mar; 57(3):1379-84. PubMed ID: 23295935
[TBL] [Abstract][Full Text] [Related]
25. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol.
Semengue ENJ; Santoro MM; Ndze VN; Dambaya B; Takou D; Teto G; Nka AD; Fabeni L; Wiyeh A; Ceccherini-Silberstein F; Colizzi V; Perno CF; Fokam J
Syst Rev; 2020 Apr; 9(1):93. PubMed ID: 32334643
[TBL] [Abstract][Full Text] [Related]
27. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
28. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
[No Abstract] [Full Text] [Related]
31. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
32. Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.
Pham HT; Alves BM; Yoo S; Xiao MA; Leng J; Quashie PK; Soares EA; Routy JP; Soares MA; Mesplède T
J Antimicrob Chemother; 2021 Feb; 76(3):639-647. PubMed ID: 33184634
[TBL] [Abstract][Full Text] [Related]
33. HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study.
Devendra A; Kohler M; Letsika M; Khooa H; Motaboli L; Lerotholi M; Tschumi N; Labhardt ND; Brown JA
AIDS; 2024 Jun; 38(7):1013-1023. PubMed ID: 38381717
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
[TBL] [Abstract][Full Text] [Related]
35. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.
Inzaule SC; Hamers RL; Doherty M; Shafer RW; Bertagnolio S; Rinke de Wit TF
Lancet Infect Dis; 2019 Jul; 19(7):e246-e252. PubMed ID: 30902440
[TBL] [Abstract][Full Text] [Related]
36. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.
Namayanja GA; Da Silva JF; Elur B; Nasirumbi PM; Raizes E; Ssempiira J; Nazziwa E; Nabukenya M; Sewanyana I; Balaba J; Ntale J; Calnan J; Birabwa E; Akao J; Mwangi C; Naluguza M; Ahimbisibwe A; Katureebe C; Nabadda S; Nelson L; Dirlikov E
PLoS One; 2024; 19(6):e0305129. PubMed ID: 38923981
[TBL] [Abstract][Full Text] [Related]
37. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
[TBL] [Abstract][Full Text] [Related]
38. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.
Piacentini D; Lanzafame M; Rizzardo S; Chiesi S; Lattuada E; Mehrabi S; Zamboni G; Mazzi R; Tacconelli E; Vento S
Int J STD AIDS; 2020 Dec; 31(14):1407-1410. PubMed ID: 33081650
[TBL] [Abstract][Full Text] [Related]
39. High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up.
Rutstein SE; Chen JS; Nelson JAE; Phiri S; Miller WC; Hosseinipour MC
AIDS Res Ther; 2019 Feb; 16(1):5. PubMed ID: 30795780
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings.
Fokam J; Ngoufack Jagni Semengue E; Molimbou E; Etame NK; Santoro MM; Takou D; Mossiang L; Meledie AP; Chenwi CA; Yagai B; Nka AD; Dambaya B; Teto G; Ka'e AC; Beloumou GA; Ndjeyep SCD; Fainguem N; Abba A; Kengni AMN; Tchouaket MCT; Bouba NP; Billong SC; Djubgang R; Saounde ET; Sosso SM; Kouanfack C; Bissek AZ; Eben-Moussi E; Colizzi V; Perno CF; Ceccherini-Silberstein F; Ndjolo A
Microbiol Spectr; 2022 Dec; 10(6):e0342022. PubMed ID: 36259973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]